チェックポイント阻害剤の世界市場レポート 2025年

チェックポイント阻害剤の市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.1％で556億4,000万米ドルに成長します。予測期間における成長の要因は、適応症の拡大、バイオマーカーの発見、併用療法、個別化医療、適応症の拡大などです。予測期間における主な動向には、精密免疫療法、免疫チェックポイント併用療法、細胞療法統合、バイオシミラー、免疫療法併用療法などがあります。

世界のがん罹患率の増加が、今後数年間のチェックポイント阻害剤市場の成長を牽引すると予想されます。がんは、制御不能な異常細胞の増殖と拡散を特徴とする疾患の集合体であり、異常細胞は周囲の組織を侵し、身体の他の部位に転移する可能性があります。がん患者の増加は、人口の高齢化、不健康なライフスタイル（喫煙や食生活の乱れなど）、環境暴露（汚染や放射線など）、遺伝的要因、HPVや肝炎などの感染症などの要因に起因しています。チェックポイント阻害剤は、免疫細胞を阻害するタンパク質をブロックすることで、免疫系がより効果的にがん細胞を認識し攻撃できるようにします。例えば、2024年9月、米国に本部を置く専門組織である米国がん協会は、2050年までに世界の男性のがん罹患者数は2022年の1,030万人から1,900万人へと84％増加し、がん関連死は2022年の540万人から1,050万人へと93％増加すると予測しています。その結果、世界のがん罹患率の上昇により、チェックポイント阻害剤の需要が大幅に高まると予想されます。

ヘルスケア支出の増加は、今後のチェックポイント阻害剤市場の成長を促進すると予測されています。ヘルスケア支出とは、特定の期間（通常は特定の国や地域内）において、ヘルスケア商品やサービスに割り当てられる総財源を指します。チェックポイント阻害剤に関連するこの支出には、医薬品開発や製造から患者アクセスやサポートサービスまで、幅広い活動が含まれます。このような革新的ながん治療を、安全性と有効性を維持しながら確実に利用できるようにするためには、このような活動が不可欠です。例えば、2024年10月、米国政府機関であるメディケアメディケイドサービスセンターの報告書によると、2022年の病院支出は2.2％増の1兆3,550億米ドルに達し、医師・臨床サービスへの支出は2.7％増の8,849億米ドルで、いずれも2021年に比べて緩やかな伸び率でした。さらに、国民医療費（NHE）は2023年には7.5％増加し、GDP成長率6.1％を上回ると予測されています。したがって、ヘルスケア支出の増加動向は、チェックポイント阻害剤市場の成長に大きく寄与すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のチェックポイント阻害剤市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のチェックポイント阻害剤市場：成長率分析
• 世界のチェックポイント阻害剤市場の実績：規模と成長、2019～2024年
• 世界のチェックポイント阻害剤市場の予測：規模と成長、2024～2029年、2034年
• 世界のチェックポイント阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のチェックポイント阻害剤市場：薬剤別、実績と予測、2019～2024年、2024～2029年、2034年
• PD-1阻害剤
• PD-L1阻害剤
• CTLA-4
• キメラ抗原受容体T細胞
• その他
• 世界のチェックポイント阻害剤市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 肺がん
• 腎臓がん
• 血液がん
• 膀胱がん
• メラノーマ
• その他
• 世界のチェックポイント阻害剤市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のチェックポイント阻害剤市場：PD-1阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ペンブロリズマブ（キイトルーダ）
• ニボルマブ（オプジーボ）
• 世界のチェックポイント阻害剤市場：PD-L1阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• アテゾリズマブ（テセントリク）
• デュルバルマブ（イムフィンジ）
• アベルマブ（バベンチオ）
• 世界のチェックポイント阻害剤市場：CTLA-4のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• イピリムマブ（ヤーボイ）
• 世界のチェックポイント阻害剤市場：キメラ抗原受容体T細胞のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• CAR-T細胞療法製品
• 世界のチェックポイント阻害剤市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 併用療法
• 新興チェックポイント阻害剤

第7章 地域別・国別分析

• 世界のチェックポイント阻害剤市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のチェックポイント阻害剤市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• チェックポイント阻害剤市場：競合情勢
• チェックポイント阻害剤市場：企業プロファイル
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Incyte Corporation
• Novartis AG
• NewLink Genetics Corporation
• Seattle Genetics Inc.
• Celldex Therapeutics
• GlaxoSmithKline plc
• Innate Pharma S.A.
• Ono Pharmaceutical Co. Ltd.
• Juno Therapeutics
• Kite Pharma
• Eli Lilly and Company（ARMO Biosciences）
• Fortress Biotech
• Argenx SE
• MacroGenics
• CureTech

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• チェックポイント阻害剤市場2029：新たな機会を提供する国
• チェックポイント阻害剤市場2029：新たな機会を提供するセグメント
• チェックポイント阻害剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Checkpoint inhibitors represent a form of immunotherapy that disrupts the interaction between immune checkpoint proteins, enabling T cells to combat cancer cells by avoiding the suppression signal. Among these medications, one targets the checkpoint protein CTLA-4.

Within the realm of checkpoint inhibitors, the primary drug categories include PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, chimeric antigen receptor T-cells (CAR-T), and other variants. PD-1 and PD-L1 inhibitors specifically hinder the function of immune checkpoint proteins present on cell surfaces, aiding in the treatment of conditions like lung cancer, renal cancer, blood cancer, bladder cancer, melanoma, and more. These therapies find application across diverse sectors encompassing hospital pharmacies, retail pharmacies, and online pharmacy services.

The checkpoint inhibitors market research report is one of a series of new reports from The Business Research Company that provides checkpoint inhibitors market statistics, including checkpoint inhibitors industry global market size, regional shares, competitors with a checkpoint inhibitors market share, detailed checkpoint inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the checkpoint inhibitors industry. This checkpoint inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The checkpoint inhibitors market size has grown rapidly in recent years. It will grow from $32.41 billion in 2024 to $37.88 billion in 2025 at a compound annual growth rate (CAGR) of 16.9%. The growth in the historic period can be attributed to rising incidence of cancer, increasing awareness of checkpoint inhibitors, expanding range of approved checkpoint inhibitors, research and development on checkpoints novel inhibitors, clinical trials and research.

The checkpoint inhibitors market size is expected to see rapid growth in the next few years. It will grow to $55.64 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to expanding indications, biomarker discovery, combination therapies, personalized medicine, and expanded indications. Major trends in the forecast period include precision immunotherapy, immune checkpoint combinations, cell therapy integration, biosimilars, and immunotherapy combinations.

The increasing prevalence of cancer cases worldwide is expected to drive the growth of the checkpoint inhibitors market in the coming years. Cancer is a collection of diseases characterized by the uncontrolled proliferation and dissemination of abnormal cells, which can invade surrounding tissues and spread to other areas of the body. The rise in cancer cases is attributed to factors such as aging populations, unhealthy lifestyles (including smoking and poor diet), environmental exposures (such as pollution and radiation), genetic factors, and infections like HPV and hepatitis. Checkpoint inhibitors work by blocking proteins that inhibit immune cells, allowing the immune system to more effectively recognize and attack cancer cells. For example, in September 2024, the American Cancer Society, a professional organization based in the U.S., projected that by 2050, the number of global cancer cases in men will increase by 84%, rising from 10.3 million in 2022 to 19 million, while cancer-related deaths are expected to grow by 93%, from 5.4 million in 2022 to 10.5 million. Consequently, the rising incidence of cancer worldwide is anticipated to significantly enhance the demand for checkpoint inhibitors.

The rising healthcare expenditure is anticipated to drive the growth of the checkpoint inhibitors market in the future. Healthcare expenditure refers to the total financial resources allocated to healthcare goods and services over a specific period, usually within a particular country or region. This expenditure related to checkpoint inhibitors includes a broad spectrum of activities, ranging from drug development and manufacturing to patient access and support services. It is vital for ensuring the availability of these innovative cancer treatments while maintaining their safety and efficacy. For example, in October 2024, a report from the Centers for Medicare and Medicaid Services, a U.S. government agency, indicated that in 2022, hospital expenditures rose by 2.2% to reach $1,355.0 billion, while expenditures for physician and clinical services increased by 2.7% to $884.9 billion, both reflecting a more moderate growth rate compared to 2021. Additionally, national health expenditure (NHE) is projected to have grown by 7.5% in 2023, exceeding the GDP growth rate of 6.1%. Therefore, the upward trend in healthcare expenditure is expected to significantly contribute to the growth of the checkpoint inhibitors market.

Leading companies in the checkpoint inhibitor market are actively developing advanced technologies, including oral checkpoint inhibitors. Many cancer patients do not respond effectively to traditional immune checkpoint inhibitors, which is where oral checkpoint inhibitors come in. These innovative cancer immunotherapy drugs are designed to be taken orally and work by blocking immune checkpoints such as PD-1/PD-L1, thereby enhancing the immune system's ability to recognize and attack cancer cells. For example, in September 2024, OmRx Oncology, a biopharmaceutical company based in the U.S., launched OX-4224, an oral checkpoint inhibitor that targets the PD-1/PD-L1 pathway specifically for non-small cell lung cancer (NSCLC). This investigational drug aims to offer a more affordable alternative to existing biologic checkpoint inhibitors, thereby increasing access to cancer immunotherapy worldwide. A Phase 2 study is planned in India to evaluate its safety and efficacy in patients with advanced NSCLC. Additionally, OmRx intends to expand its use in low- and middle-income countries, focusing on enhancing cancer care globally.

Keytruda (pembrolizumab), an immunotherapy drug categorized as a checkpoint inhibitor, exemplifies the innovation in the checkpoint inhibitors market. Merck & Co., Inc. obtained FDA approval in March 2022 for Keytruda to treat patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial carcinoma. Keytruda's mechanism involves enabling the immune system to identify and combat cancer cells by blocking checkpoint proteins, offering an effective treatment avenue either individually or in combination with other cancer therapies.

In July 2024, Boehringer Ingelheim, a pharmaceutical company based in Germany, acquired Nerio Therapeutics for a sum of up to $1.3 billion. This acquisition allows Boehringer to access Nerio's preclinical research on checkpoint inhibitors, which focuses on inhibiting the enzymes PTPN1 and PTPN2 to boost the immune system's response to tumors. Nerio Therapeutics is a biotechnology startup located in the U.S. that specializes in developing immuno-oncology drugs and preclinical immune checkpoint inhibitors.

Major companies operating in the checkpoint inhibitors market include AstraZeneca plc, Bristol-Myers Squibb Company, Merck & Co. Inc., Roche Holding AG, Pfizer Inc., Incyte Corporation, Novartis AG, GlaxoSmithKline plc, Innate Pharma S.A., Ono Pharmaceutical Co. Ltd., Eli Lilly and Company, Sanofi S.A, AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bayer AG, Boehringer Ingelheim International GmbH, Celgene Corporation, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Kyowa Kirin Co. Ltd., Johnson & Johnson, Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Zai Lab Limited

North America was the largest region in the checkpoint inhibitors market in 2024. The Middle East is expected to be the fastest growing region in the global checkpoint inhibitors market share during the forecast period. The regions covered in the checkpoint inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the checkpoint inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The checkpoint inhibitors market consists of sales of atezolizumab, avelumab, and durvalumab. Values in this market are 'factory gate values,' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Checkpoint Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on checkpoint inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for checkpoint inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The checkpoint inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug: PD-1 Inhibitors; PD-L1 Inhibitors; CTLA-4; Chimeric Antigen Receptor T-cell; Other Drugs
• 2) By Application: Lung Cancer; Renal Cancer; Blood Cancer; Bladder Cancer; Melanoma; Other Applications
• 3) By End-Users: Hospitals Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By PD-1 Inhibitors: Pembrolizumab (Keytruda); Nivolumab (Opdivo)
• 2) By PD-L1 Inhibitors: Atezolizumab (Tecentriq); Durvalumab (Imfinzi); Avelumab (Bavencio)
• 3) By CTLA-4: Ipilimumab (Yervoy)
• 4) By Chimeric Antigen Receptor T-cell: CAR T-cell Therapy Products
• 5) By Other Drugs: Combination Therapies; Emerging Checkpoint Inhibitors
• Companies Mentioned: AstraZeneca plc; Bristol-Myers Squibb Company; Merck & Co. Inc.; Roche Holding AG; Pfizer Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Checkpoint Inhibitors Market Characteristics

3. Checkpoint Inhibitors Market Trends And Strategies

4. Checkpoint Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Checkpoint Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Checkpoint Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Checkpoint Inhibitors Market Growth Rate Analysis
• 5.4. Global Checkpoint Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Checkpoint Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Checkpoint Inhibitors Total Addressable Market (TAM)

6. Checkpoint Inhibitors Market Segmentation

• 6.1. Global Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PD-1 Inhibitors
• PD-L1 Inhibitors
• CTLA-4
• Chimeric Antigen Receptor T-cell
• Other Drugs
• 6.2. Global Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lung Cancer
• Renal Cancer
• Blood Cancer
• Bladder Cancer
• Melanoma
• Other Applications
• 6.3. Global Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Checkpoint Inhibitors Market, Sub-Segmentation Of PD-1 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pembrolizumab (Keytruda)
• Nivolumab (Opdivo)
• 6.5. Global Checkpoint Inhibitors Market, Sub-Segmentation Of PD-L1 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atezolizumab (Tecentriq)
• Durvalumab (Imfinzi)
• Avelumab (Bavencio)
• 6.6. Global Checkpoint Inhibitors Market, Sub-Segmentation Of CTLA-4, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ipilimumab (Yervoy)
• 6.7. Global Checkpoint Inhibitors Market, Sub-Segmentation Of Chimeric Antigen Receptor T-cell, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• CAR T-cell Therapy Products
• 6.8. Global Checkpoint Inhibitors Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Combination Therapies
• Emerging Checkpoint Inhibitors

7. Checkpoint Inhibitors Market Regional And Country Analysis

• 7.1. Global Checkpoint Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Checkpoint Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Checkpoint Inhibitors Market

• 8.1. Asia-Pacific Checkpoint Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Checkpoint Inhibitors Market

• 9.1. China Checkpoint Inhibitors Market Overview
• 9.2. China Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Checkpoint Inhibitors Market

• 10.1. India Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Checkpoint Inhibitors Market

• 11.1. Japan Checkpoint Inhibitors Market Overview
• 11.2. Japan Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Checkpoint Inhibitors Market

• 12.1. Australia Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Checkpoint Inhibitors Market

• 13.1. Indonesia Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Checkpoint Inhibitors Market

• 14.1. South Korea Checkpoint Inhibitors Market Overview
• 14.2. South Korea Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Checkpoint Inhibitors Market

• 15.1. Western Europe Checkpoint Inhibitors Market Overview
• 15.2. Western Europe Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Checkpoint Inhibitors Market

• 16.1. UK Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Checkpoint Inhibitors Market

• 17.1. Germany Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Checkpoint Inhibitors Market

• 18.1. France Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Checkpoint Inhibitors Market

• 19.1. Italy Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Checkpoint Inhibitors Market

• 20.1. Spain Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Checkpoint Inhibitors Market

• 21.1. Eastern Europe Checkpoint Inhibitors Market Overview
• 21.2. Eastern Europe Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Checkpoint Inhibitors Market

• 22.1. Russia Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Checkpoint Inhibitors Market

• 23.1. North America Checkpoint Inhibitors Market Overview
• 23.2. North America Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Checkpoint Inhibitors Market

• 24.1. USA Checkpoint Inhibitors Market Overview
• 24.2. USA Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Checkpoint Inhibitors Market

• 25.1. Canada Checkpoint Inhibitors Market Overview
• 25.2. Canada Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Checkpoint Inhibitors Market

• 26.1. South America Checkpoint Inhibitors Market Overview
• 26.2. South America Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Checkpoint Inhibitors Market

• 27.1. Brazil Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Checkpoint Inhibitors Market

• 28.1. Middle East Checkpoint Inhibitors Market Overview
• 28.2. Middle East Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Checkpoint Inhibitors Market

• 29.1. Africa Checkpoint Inhibitors Market Overview
• 29.2. Africa Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Checkpoint Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. Checkpoint Inhibitors Market Competitive Landscape
• 30.2. Checkpoint Inhibitors Market Company Profiles
  • 30.2.1. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Checkpoint Inhibitors Market Other Major And Innovative Companies

• 31.1. Incyte Corporation
• 31.2. Novartis AG
• 31.3. NewLink Genetics Corporation
• 31.4. Seattle Genetics Inc.
• 31.5. Celldex Therapeutics
• 31.6. GlaxoSmithKline plc
• 31.7. Innate Pharma S.A.
• 31.8. Ono Pharmaceutical Co. Ltd.
• 31.9. Juno Therapeutics
• 31.10. Kite Pharma
• 31.11. Eli Lilly and Company (ARMO Biosciences)
• 31.12. Fortress Biotech
• 31.13. Argenx SE
• 31.14. MacroGenics
• 31.15. CureTech

32. Global Checkpoint Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Checkpoint Inhibitors Market

34. Recent Developments In The Checkpoint Inhibitors Market

35. Checkpoint Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 Checkpoint Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Checkpoint Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Checkpoint Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer